- Home
- BQ vs PPBT Comparison
BQ vs PPBT Comparison
Compare BQ & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BQ
- PPBT
- Stock Information
- Founded
- BQ 2008
- PPBT 2010
- Country
- BQ China
- PPBT Israel
- Employees
- BQ N/A
- PPBT N/A
- Industry
- BQ Other Specialty Stores
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- BQ Consumer Discretionary
- PPBT Health Care
- Exchange
- BQ Nasdaq
- PPBT Nasdaq
- Market Cap
- BQ 6.0M
- PPBT 7.1M
- IPO Year
- BQ 2020
- PPBT N/A
- Fundamental
- Price
- BQ $2.20
- PPBT $2.73
- Analyst Decision
- BQ
- PPBT Strong Buy
- Analyst Count
- BQ 0
- PPBT 1
- Target Price
- BQ N/A
- PPBT $33.00
- AVG Volume (30 Days)
- BQ 11.4K
- PPBT 16.2K
- Earning Date
- BQ 04-29-2025
- PPBT 05-20-2025
- Dividend Yield
- BQ N/A
- PPBT N/A
- EPS Growth
- BQ N/A
- PPBT N/A
- EPS
- BQ N/A
- PPBT N/A
- Revenue
- BQ $81,208,354.00
- PPBT N/A
- Revenue This Year
- BQ N/A
- PPBT N/A
- Revenue Next Year
- BQ N/A
- PPBT N/A
- P/E Ratio
- BQ N/A
- PPBT N/A
- Revenue Growth
- BQ N/A
- PPBT N/A
- 52 Week Low
- BQ $1.62
- PPBT $2.00
- 52 Week High
- BQ $7.40
- PPBT $20.60
- Technical
- Relative Strength Index (RSI)
- BQ 53.53
- PPBT 51.95
- Support Level
- BQ $1.79
- PPBT $2.67
- Resistance Level
- BQ $2.23
- PPBT $2.75
- Average True Range (ATR)
- BQ 0.20
- PPBT 0.21
- MACD
- BQ 0.06
- PPBT 0.04
- Stochastic Oscillator
- BQ 68.95
- PPBT 67.19
About BQ Boqii Holding Limited representing
Boqii Holding Ltd operates in the business of selling pet products through online stores. The store provides pet foods, health products, pet grooming products, pet bathing products, pet toys, fish tank, aquatic fertilizer, temperature control equipment, oxygen pump and other related products. Also, the company sells its products through offline channels to pet stores and hospitals.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.